Insights

Why the Creso Pharma (ASX:CPH) share price is rocketing 16% higher today

The Creso Pharma Ltd (ASX:CPH) share price is rocketing higher on Thursday. Here’s what you need to know about this strong gain…
The post Why the Creso Pharma (ASX:CPH) share price is rocketing 16% higher today appeared first on The Motley Fool Australia. –

rocketing asx share price represented by man riding golden dollar sign speeding through clouds

The market may be tumbling lower again on Thursday, but the same cannot be said for the Creso Pharma Ltd (ASX: CPH) share price.

In afternoon trade the cannabis company’s shares are up a sizeable 16% to 22 cents.

This gain means the Creso Pharma share price is now up over 250% since this time last year.

What is driving the Creso Pharma share price higher today?

The strong gain by the Creso Pharma share price today appears to have been driven by investors taking advantage of a recent pullback.

In fact, although they have jumped 16% today, the company’s shares are still trading below the high they reached on Monday morning of 23 cents.

What’s been happening?

Interestingly, investors have been selling the company’s shares since it announced an acquisition earlier this week. This could be a sign that some are not convinced by Creso Pharma’s foray into the psychedelics market.

According to that announcement, the company has signed an agreement to acquire Halucenex Life Sciences. It is a Canada-based psychedelics company focused on developing treatments for Treatment Resistant Depression in individuals suffering from PTSD, and other mental health illnesses.

Management notes that the acquisition provides Creso Pharma with direct entry into the emerging psychedelic medicines market, creating a diversified natural medicines company to improve mental health and wellness.

It believes the combined group will allow the Halucenex business to benefit from a number of significant synergies, ultimately fast tracking the company to early revenues.

“A major milestone”

Creso Pharma’s Non-Executive Chairman, Adam Blumenthal, is very positive on the acquisition and believes it is a major milestone for the company.

He said: “This is a major milestone for Creso Pharma and marks our evolution into a broader based pharmaceutical business. Creso will now sell its trusted cannabis products and progress the commercialisation of a range of psychedelic-assisted psychotherapy treatments. Our entry into this market provides the Company with another lucrative vertical and an additional near term revenue stream.”

“Mental health and PTSD are becoming detrimental to our society and this has been highlighted in the last 12 months. These conditions have been exacerbated by COVID-19 and the available treatments are shown to have limited effectiveness and many side effects. Psychedelic-assisted therapy is a new alternative treatment route, which has considerable promise.”

“The acquisition of Halucenex will strengthen our presence in Canada, as well as provide a number of opportunities in drug development which will inevitably lead to further new market entries and commercialisation opportunities.“

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the Creso Pharma (ASX:CPH) share price is rocketing 16% higher today appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!